Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

139.81 -3.55 (-2.48%)
Streaming Delayed Price Updated: 3:39 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
Nike, Carnival And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
It has a good shot at commercializing a drug to treat a common liver disease. 
Via The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street
This company is on the brink of a major breakthrough. 
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
Via Investor Brand Network
The Latest Analyst Ratings for Madrigal Pharmaceuticals
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Two key tailwinds appear to be lifting the stock today. 
Via The Motley Fool
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures. 
Via Investor's Business Daily
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months. 
Via InvestorPlace
Analyst Expectations for Madrigal Pharmaceuticals's Future
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Slumping Today
The biotech's shares briefly plunged following its 2023 Q1 earnings report. 
Via The Motley Fool
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Novo Nordisk received some good news in a recent physician survey. 
Via The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Recent moves to the upside could be the beginning of a much larger bull run. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.